Cargando…
HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease
In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss homeodomain-interacting-protein...
Autores principales: | Nugent, Melinda M., Lee, Kyung, He, John Cijiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411988/ https://www.ncbi.nlm.nih.gov/pubmed/25972814 http://dx.doi.org/10.3389/fphys.2015.00132 |
Ejemplares similares
-
Role of HIPK2 in kidney fibrosis
por: Fan, Ying, et al.
Publicado: (2014) -
Tubular HIPK2 is a key contributor to renal fibrosis
por: Xiao, Wenzhen, et al.
Publicado: (2020) -
Systems approach identifies HIPK2 as a critical regulator of kidney fibrosis
por: Jin, Yuanmeng, et al.
Publicado: (2012) -
circHIPK3 Exacerbates Folic Acid-Induced Renal Tubulointerstitial Fibrosis by Sponging miR-30a
por: Wu, Yan, et al.
Publicado: (2022) -
SIRT1 Is a Potential Drug Target for Treatment of Diabetic Kidney Disease
por: Zhong, Yifei, et al.
Publicado: (2018)